This evidence indicated that the anti-cancer potential of HDAC inhibitors could be promoted in combination with PI3K inhibitors against tamoxifen-resistant breast cancer cells through the direction of the cancer cells to the S phase. This evidence concerns the gene HDAC9 and cancer.